Advertisement

Organisation › Details
Orexo (Group)
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. The company has four commercialized products, several projects developed in partnership as well as three proprietary development programs. Orexo's registered products are Abstral® for the treatment of break through cancer pain, sold by Kyowa Hakko Kirin/ProStrakan Group plc. in Europe and in the USA, the sleeping pill Edluar™, sold by Meda in the USA, as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary Kibion. *
![]() |
Start | 1995-01-01 established_pre |
Today | Orexo AB (OMX Nordic List, Mid Cap: ORX) | |
Predecessor | Diabact AB | |
![]() |
Industry | drug delivery technology (drug formulation technology) |
Industry 2 | diagnostics (medical/biological) | |
![]() |
Person | Sørensen, Nikolaj (Orexo 201110– CCO before Pfizer AB + Boston Consulting Group) |
Person 2 | Juuel, Henrik (Orexo 2013Q3– CFO) | |
![]() |
Region | Uppsala |
Country | Sweden | |
Street | 32A Virdings allé | |
City | 751 05 Uppsala | |
Tel | +46-18-780-8800 | |
Fax | 46-18-780-8888 | |
Address record changed: 2012-07-22 | ||
Basic data | Employees | n. a. |
Currency | SEK | |
Cash | 91,900,000 (2013-09-30) | |
* Document for »About Section«: | ||
Record changed: 2017-04-01 |
Advertisement

More documents for Orexo (Group)
- [1] Orexo AB. (8/6/14). "Press Release: OX-MPI Project Returned to Orexo". Uppsala....
- [2] Orexo AB. (10/23/13). "Press Release: Interim Report January–September 2013"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top